ReviewA survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations
Introduction
Although the death toll from HIV/AIDS over the last quarter century has reached many millions, AIDS has become a manageable chronic disease. An impressive range of compounds (exactly 25) have so far been approved for HIV/AIDS treatment (De Clercq, 2007). Combination therapy with three or more antiretrovirals (ARV) provides relief of symptomatic disease, with most patients achieving increased CD4 levels and undetectable viral load in circulating blood plasma. Significant progress has been made for increased access to ARVs, with over 2 million patients in developing countries receiving ARVs at this time (1Q2008). The fixed-dose combination (FDC) “triomune™” (AZT + 3TC + nevirapine) from Cipla presently sells for approximately $95–140 per patient year, and is the standard first-line FDC in many developing countries. The demonstrated clinical superiority of “Atripla®” (EFV + TDF + FTC) (De Clercq, 2006) and new WHO recommendations have created significant pressure to establish this as a new standard for first-line treatment. One of the major constraints for treatment access is cost. Approximately 65–90% of the cost of ARV therapy derives from the active pharmaceutical ingredient (API).
There is an urgent need to find cheaper alternatives for the production of critical ARVs. This paper discusses methods of producing the APIs efavirenz, emtricitabine, tenofovir disoproxil fumarate, abacavir, ritonavir, lopinavir and atazanavir. With increasing need for improved therapies, there is a strong economic interest in the production of these compounds. This paper describes the most useful commercial processes to produce these compounds. The present work is not exhaustive, but aims to analyze the present situation concerning production costs and favorable alternatives.
Previous reviews (for example, Izawa and Onishi, 2006, De Clercq, 2001, De Clercq, 2005, Painter et al., 2004, Rodriguez-Barrios and Gago, 2004, Stolk and Lüers, 2004, Peçanha et al., 2002, De Clercq, 1998, Flexner, 1998, Wlodawer and Vondrasek, 1998, Antunes, 1996) emphasized the synthesis of particular classes of compounds or disclosed the development of these APIs.
Section snippets
Background
API costs represent a substantial majority of the overall cost of a finished dosage form. The synthesis of an API usually requires several chemical processing steps in which new chemical bonds are formed and molecular complexity increases. API processes are normally carried out in solution, thereby limiting overall process efficiency. Formulation of APIs into a finished dosage form is usually a single process without a change in molecular complexity. Formulation processes typically utilize
Efavirenz
Efavirenz (EFV) was discovered at the Merck Research Laboratories and licensed to Dupont Pharmaceuticals. Dupont carried EFV through development and commercialization. It is marketed as Sustiva® (Bristol-Myers Squibb) and Stocrin® (Merck). Young et al. (1996) obtained the original patent on the synthesis and HIV RT inhibition properties of efavirenz (5). Other researchers have improved this process (Radesca et al., 1997, Patel et al., 1999a, Patel et al., 1999b, Patel et al., 2000). The initial
Tenofovir disoproxil fumarate (TDF)
Tenofovir disoproxil fumarate is an acyclic nucleotide inhibitor of HIV-1 reverse transcriptase (for review, see De Clercq and Holý, 2005). The first members of this series to be synthesized were PMPA, 9-[2-(phosphonomethoxypropyl) adenine] 12 (Arimilli et al., 1997, Tsai et al., 1995) and PMEA, 9-[2-(phosphonomethoxyethyl) adenine] 13 (Kim et al., 1990, Starrett et al., 1994). The efficacy of the (R)-enantiomer of PMPA against HIV-1 reverse transcriptase was published by Balzarini et al., 1993
Emtricitabine
Emtricitabine, FTC (Emtriva®) is an inhibitor of HIV-1 reverse transcriptase for once-daily antiretroviral therapy (Cahn, 2004, Anon., 2004). Emtricitabine is a fluorinated l-nucleoside (Pankiewicz, 2000, Wang et al., 1998) closely related in structure and synthesis to lamivudine, 3TC (Coates et al., 2001). The use of emtricitabine has been restricted to co-dosing with TDF (Truvada™). Schinazi et al. (1992) described (−) and (±)-cis-5-fluoro-1-1[2-hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine,
Abacavir
The Wellcome Research Group described the production of Abacavir in two patents (Daluge, 1991a, Daluge, 1991b). These processes were reviewed in Kleeman's Encyclopedia (Kleemann and Engel, 1999). Abacavir 27 is a cyclopropylamine derivative of carbovir 28.
Rac-cis-(+)-carbovir 28 (Vince and Hua, 1990) can be obtained from reacting rac-cis-4-(hydroxymethyl)cyclopentenylamine 29 and 2-amino-4,6-dichloropyrimidine 30 to give intermediate 31. This is followed by coupling with the diazonium salt of p
Ritonavir and lopinavir
Ritonavir (RTV, 41) and lopinavir (LPV, 42) are protease inhibitors that share the same hydroxyethylene dipeptide core 43 (Kempf et al., 1995).
Synthetic approaches to 41 and 42 by making peptide bonds are obviously practical. Sequential coupling of the amines of a pseudo-C2 symmetric core with activated ester “wings” suggests the option of a common intermediate to both RTV and LPV.
Different strategies in developing industrial routes to lopinavir and ritonavir deserve attention. Kaletra® is the
Atazanavir
Atazanavir (BMS-232632, 58) is an aza-peptide isostere first registered in the USA in 2005 (Robinson et al., 2000, Gong et al., 2000). Voluntary licenses from the innovator company Bristol–Myers Squibb have been granted for generic production of this drug in India.
Bristol–Myers Squibb (Xu et al., 2002) has published details of the process used for production. Boronic acid derivative 59 is submitted to the Suzuki–Miyaura coupling with 2-bromopyridine using Pd catalysis. The reaction product 60
Conclusion
From the literature it is very clear that there are several suitable (and simple) processes to produce APIs of the selected critical ARV drugs. In some cases new routes to some feedstocks are needed in order to drive cost reduction for access. There is significant scope to reduce the production costs of several critical APIs. Most importantly, Izawa and Onishi (2006) have recently disclosed some industrial process to manufacture the core of the HIV protease inhibitors.
Acknowledgements
Support from World Health Organization (WHO), The Brazilian National Research Council (CNPq), The Brazilian Ministry of Education (CAPES) and The Rio de Janeiro Research Foundation (FAPERJ) is gratefully acknowledged. We are also grateful to Amolo Okero (WHO) for her contribution in organizing the final manuscript and to Jos Perriens (WHO) for substantial review and input towards the completion of the paper. The Clinton HIV/AIDS Initiative provided valuable data on the number of patients on
References (161)
- et al.
Synthesis of l-cyclopentenyl nucleosides using ring-closing metathesis and palladium-mediated allylic alkylation methodologies
Tetrahedron
(2004) - et al.
Palladium catalyzed cross-coupling reactions of arylboronic acids with π-deficient heteroaryl chlorides
Tetrahedron
(1992) - et al.
Efficient synthesis of various acycloalkenyl derivatives of pyrimidine using cross-metathesis and Pd(0) methodologies
Tetrahedron
(2005) - et al.
An asymmetric synthesis of (−)-carbovir
Tetrahedron: Asymm.
(1994) - et al.
Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems
Biochem. Biophys. Res. Commun.
(1996) - et al.
Facile inversion of configuration of N-BOC-beta-aminoalcohols via SN2 cyclization to oxazolidinones
Tetrahedron Lett.
(2000) - et al.
[2 + 3]-Cycloadditions of enantiomerically pure oxazoline-N-oxides 1: a short stereoselective synthesis of (+)-carbovir
Tetrahedron Lett.
(1995) - et al.
The silicon effect on the regioselectivity of the Tsuji-Trost reaction. Experimental and theoretical approaches
J. Organom. Chem.
(2003) - et al.
2-(Fluorophenyl)pyridines by the Suzuki–Miyaura method: Ag2O accelerates coupling over undesired ipso substitution (SNAr) of fluorine
Tetrahedron Lett.
(2003) - et al.
Palladium-catalyzed Suzuki–Miyaura reaction using aminophosphine as ligand
Tetrahedron Lett.
(2003)
Water-mediated transition-metal-free Tsuji–Trost-type reaction
Tetrahedron Lett.
Enzymic resolution of oxathiolane intermediates—an alternative approach to the anti-viral agent Lamivudine (3TC™)
Tetrahedron: Asymm.
New developments in the enantioselective synthesis of cyclopentyl carbocyelic nucleosides
Tetrahedron
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
Antivir. Res.
Antiviral drug discovery and development: where chemistry meets with biomedicine
Antivir. Res.
A concise synthesis of aza-dipeptide isosteres
Tetrahedron Lett.
A convenient synthesis of enaminones using tandem acetonitrile condensation, grignard addition
Tetrahedron Lett.
Highly enantioselective cyanosilylation of aldehydes catalyzed by a Lewis acid–Lewis base bifunctional catalyst
Tetrahedron
The preparation of a stable 2-pyridylboronate and its reactivity in the Suzuki–Miyaura cross-coupling reaction
Tetrahedron Lett.
A convenient preparation of dityrosine via Miyaura borylation–Suzuki coupling of iodotyrosine derivatives
Tetrahedron Lett.
Synthesis of acyclic nucleoside and nucleotide analogues from amino acids: a convenient approach to a PMEA–PMPA hybrid
Tetrahedron
Synthesis of a dicyclobutylideneethane derivative via sequential palladium-catalyzed Miyaura borylation and Suzuki coupling
Tetrahedron Lett.
Versatile synthetic routes to threo-beta-amino hydroxy carboxylic acids, statine and its analogues
Bioorg. Med. Chem. Lett.
Design of orally bioavailable, symmetry-based inhibitors of HIV protease
Bioorg. Med. Chem.
Recent applications of the Suzuki–Miyaura cross-coupling reaction in organic synthesis
Tetrahedron
Stereoselective hydroazidation of amino enones: synthesis of the ritonavir/lopinavir core
Org. Lett.
Emtricitabine/tenofovir disoproxil fumarate
Drugs R. D.
Inibidores da HIV-1 Protease: Uma Revisão
Rev. Bras. Farm
Synthesis, in vitro biological evaluation and oral bioavailability of prodrugs of the antiretroviral agent 9-[2-(phosphonomethoxy)-propyl]adenine (PMA)
Antivir. Chem. Chemother.
Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine
Antimicrob. Agents Chemother.
Epoxyalcohol route to hydroxyethylene dipeptide isosteres: a new synthesis of the diaminoalcohol core of HIV-protease inhibitor ABT-538 (Ritonavir)
J. Chem. Soc. Chem. Commun.
Epoxyalcohol route to hydroxyethylene dipeptide isosteres Stereodivergent synthesis of the diamino alcohol core of ritonavir and its C-2 epimer
J. Org. Chem.
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability
J. Med. Chem.
Acylnitrene route to vicinal amino alcohols Application to the synthesis of (−)-bestatin and analogues
J. Org. Chem.
New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development
J. Med. Chem.
Stereospecific gamma-lactamase activity in a Pseudomonas fluorescens species
J. Ind. Microbiol.
A novel, one-pot ring expansion of cyclobutanones Syntheses of carbovir and aristeromycin
J. Org. Chem.
Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy
Exp. Opin. Investig. Drugs
A new strategy for the asymmetric synthesis of 1,3-oxathiolane-based nucleoside analogues
Eur. J. Org. Chem.
Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340
Nucl. Nucl. Nucl. Acids
In situ recycling of chiral ligand and surplus nucleophile for a noncatalytic reaction: amplification of process throughput in the asymmetric addition step of efavirenz (DMP 266)
Org. Process Res. Dev.
Kaletra (lopinavir/ritonavir)
Ann. Pharmacother.
An efficient asymmetric approach to carbocyclic nucleosides: asymmetric synthesis of 1592U89, a potent inhibitor of HIV reverse transcriptase
J. Org. Chem.
An efficient, general asymmetric synthesis of carbocyclic nucleosides: application of an asymmetric aldol/ring-closing metathesis strategy
J. Org. Chem.
Cited by (38)
Sustainable green technologies for synthesis of potential drugs targeted toward tropical diseases
2020, Green Approaches in Medicinal Chemistry for Sustainable Drug DesignBase catalyzed unexpected rearrangement of isatin-derived N,N′-cyclic azomethine imines and Michael addition to hindered vinylidene bisphosphonates: Access to 3,3-disubstituted oxindole-fused pyrazolidin-3-one derivatives containing bisphosphonates
2019, TetrahedronCitation Excerpt :Organophosphorus compounds continue to receive widespread attention due to their ubiquity in biological systems and their potential to serve as novel pharmaceuticals [1].
A combined TD-DFT and spectroscopic investigation of the solute-solvent interactions of efavirenz
2016, Spectrochimica Acta - Part A: Molecular and Biomolecular SpectroscopyCitation Excerpt :Efavirenz, commercially known as Sustiva® or Stocrin® (Fig. 1), is a first-line antiretroviral treatment for HIV/AIDS [1].
Evaluating the potential for the continuous processing of pharmaceutical products-a supply network perspective
2015, Chemical Engineering and Processing: Process IntensificationMicellar electrokinetic chromatography method development for determination of impurities in Ritonavir
2010, Journal of Pharmaceutical and Biomedical AnalysisCitation Excerpt :The methyl ester is less stable in the aqueous environments in which the majority of the experiments were performed in this work, which suggests that the methyl group is bound to the amide group. The ionization behavior of 5-thiazole wing is similar to the ionization of nitrophenols, considering the observed color change with pH. The esterification of 5-hydroxymethyl thiazole with p-nitrophenyl chloroformate produces an activated intermediate for coupling of 5-thiazole wing with boc-core and is a described synthetic approach [20]. The attachment of a nitrophenyl group to 5-thiazole wing was confirmed by MS, with the observation of a base peak at m/z 281 ([5-thiazole-p-nitrophenyl carbonate + H]+).